Insufficient scRNA-seq data for expression of IFNL2 at single-cell level.
Insufficient scRNA-seq data for expression of IFNL2 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
pancreas | 79% | 3.60 | 259 / 328 | 3% | 0.07 | 6 / 178 |
skin | 49% | 2.89 | 887 / 1809 | 0% | 0 | 0 / 472 |
bladder | 24% | 0.38 | 5 / 21 | 2% | 0.06 | 12 / 504 |
lung | 21% | 0.28 | 123 / 578 | 3% | 0.07 | 33 / 1155 |
thymus | 22% | 0.37 | 144 / 653 | 0% | 0.01 | 1 / 605 |
peripheral blood | 22% | 0.44 | 203 / 929 | 0% | 0 | 0 / 0 |
breast | 13% | 0.19 | 61 / 459 | 6% | 0.16 | 69 / 1118 |
ovary | 15% | 0.17 | 27 / 180 | 4% | 0.13 | 19 / 430 |
muscle | 19% | 0.25 | 154 / 803 | 0% | 0 | 0 / 0 |
brain | 19% | 0.30 | 491 / 2642 | 0% | 0.00 | 1 / 705 |
uterus | 13% | 0.21 | 22 / 170 | 5% | 0.21 | 21 / 459 |
esophagus | 12% | 0.18 | 177 / 1445 | 3% | 0.36 | 6 / 183 |
intestine | 14% | 0.19 | 134 / 966 | 2% | 0.06 | 8 / 527 |
stomach | 9% | 0.13 | 34 / 359 | 5% | 0.10 | 14 / 286 |
blood vessel | 14% | 0.18 | 184 / 1335 | 0% | 0 | 0 / 0 |
spleen | 14% | 0.17 | 33 / 241 | 0% | 0 | 0 / 0 |
prostate | 13% | 0.16 | 32 / 245 | 0% | 0.00 | 1 / 502 |
adipose | 13% | 0.18 | 154 / 1204 | 0% | 0 | 0 / 0 |
adrenal gland | 11% | 0.13 | 28 / 258 | 0% | 0 | 0 / 230 |
heart | 10% | 0.12 | 88 / 861 | 0% | 0 | 0 / 0 |
liver | 10% | 0.18 | 22 / 226 | 0% | 0 | 0 / 406 |
kidney | 7% | 0.07 | 6 / 89 | 0% | 0.01 | 4 / 901 |
tonsil | 0% | 0 | 0 / 0 | 4% | 0.13 | 2 / 45 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0051607 | Biological process | defense response to virus |
GO_0098586 | Biological process | cellular response to virus |
GO_0050778 | Biological process | positive regulation of immune response |
GO_0038196 | Biological process | type III interferon-mediated signaling pathway |
GO_0007259 | Biological process | cell surface receptor signaling pathway via JAK-STAT |
GO_0002385 | Biological process | mucosal immune response |
GO_0045087 | Biological process | innate immune response |
GO_0005615 | Cellular component | extracellular space |
GO_0005576 | Cellular component | extracellular region |
GO_0005102 | Molecular function | signaling receptor binding |
GO_0005125 | Molecular function | cytokine activity |
Gene name | IFNL2 |
Protein name | Interferon lambda-2 (IFN-lambda-2) (Cytokine Zcyto20) (Interleukin-28A) (IL-28A) |
Synonyms | ZCYTO20 IL28A |
Description | FUNCTION: Cytokine with antiviral, antitumour and immunomodulatory activities. Plays a critical role in the antiviral host defense, predominantly in the epithelial tissues. Acts as a ligand for the heterodimeric class II cytokine receptor composed of IL10RB and IFNLR1, and receptor engagement leads to the activation of the JAK/STAT signaling pathway resulting in the expression of IFN-stimulated genes (ISG), which mediate the antiviral state. Has a restricted receptor distribution and therefore restricted targets: is primarily active in epithelial cells and this cell type-selective action is because of the epithelial cell-specific expression of its receptor IFNLR1. Seems not to be essential for early virus-activated host defense in vaginal infection, but plays an important role in Toll-like receptor (TLR)-induced antiviral defense. Plays a significant role in the antiviral immune defense in the intestinal epithelium. Exerts an immunomodulatory effect by up-regulating MHC class I antigen expression. . |
Accessions | Q8IZJ0 ENST00000709041.1 ENST00000331982.6 |